Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Zigakibart in Adults With Primary IgA Nephropathy.

NCT06858319 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT06858319
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06858319 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Zigakibart in Adults With Primary IgA Nephropathy.
Lead sponsor
Novartis Pharmaceuticals
Phase
Phase 3
Overall status
Recruiting
Start date
July 28, 2025
Completion date
June 25, 2031
Enrollment
220 (estimated)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

glomerular disease, glomerulonephritis, glomerulonephritis, iga, glomerulopathy, immunoglobulin disease, kidney diseases, kidney diseases, chronic, urological diseases